Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders

Highlights • Treosulfan-based conditioning has a low toxicity profile • High level donor engraftment in marrow failure disorders • Excellent disease-free survival

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017-10, Vol.23 (10), p.1669-1677
Main Authors: Burroughs, Lauri M., MD, Shimamura, Akiko, MD, PhD, Talano, Julie-An, MD, Domm, Jennifer, MD, Baker, Kelsey, MS, Delaney, Colleen, MD, Frangoul, Haydar, MD, Margolis, David, MD, Baker, K. Scott, MD, MS, Geddis, Amy, MD, PhD, Sandmaier, Brenda M., MD, Deeg, H. Joachim, MD, Storb, Rainer, MD, Woolfrey, Ann E., MD
Format: Article
Language:English
Subjects:
Adolescent
Antilymphocyte Serum - therapeutic use
Bone Marrow Diseases - therapy
Bone marrow failure
Busulfan - analogs & derivatives
Busulfan - therapeutic use
Child
Child, Preschool
Diamond Blackfan Anemia
Disease-Free Survival
Female
Graft Survival
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation - methods
Humans
Infant
Male
Reduced-toxicity conditioning in nonmalignant diseases
Shwachman-Diamond Syndrome
Transplantation Conditioning - methods
Transplantation, Homologous
Treatment Outcome
Vidarabine - analogs & derivatives
Vidarabine - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Treosulfan-based conditioning has a low toxicity profile • High level donor engraftment in marrow failure disorders • Excellent disease-free survival
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2017.06.002